{
    "clinical_study": {
        "@rank": "138121", 
        "brief_summary": {
            "textblock": "RATIONALE: AE-941 may help to slow the growth of multiple myeloma.\n\n      PURPOSE: Phase II trial to study the effectiveness of neovastat in treating patients who\n      have relapsed or refractory multiple myeloma."
        }, 
        "brief_title": "AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma", 
        "condition": "Multiple Myeloma and Plasma Cell Neoplasm", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Plasmacytoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the confirmed tumor response rate in patients with early relapse or\n           refractory multiple myeloma treated with AE-941 (Neovastat).\n\n        -  Determine the safety of this drug in these patients.\n\n        -  Evaluate the time to progression in patients treated with this drug.\n\n        -  Evaluate the duration of tumor response (partial response, response, and complete\n           response) in patients treated with this drug.\n\n      OUTLINE: This is a multicenter, open-label study.\n\n      Patients receive oral AE-941 (Neovastat) twice daily.\n\n      Patients are followed every 4 weeks until disease progression.\n\n      PROJECTED ACCRUAL: A total of 125 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of multiple myeloma (MM) according to the Durie and Salmon criteria\n\n          -  Refractory to or in early relapse after standard chemotherapy with or without stem\n             cell transplantation\n\n          -  Measurable disease\n\n               -  Quantifiable IgM, IgG, or IgA paraprotein in serum AND/OR\n\n               -  Bence-Jones protein in urine\n\n          -  No plasma cell leukemia (more than 20% plasma cells in peripheral blood and an\n             absolute plasma cell count of at least 2,000/mm3)\n\n          -  No nonsecretory MM\n\n          -  No spinal cord compression\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  More than 6 months\n\n        Hematopoietic:\n\n          -  No clinical symptoms of hyperviscosity\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Creatinine no greater than 2 times upper limit of normal\n\n          -  Calcium no greater than 11 mg/dL\n\n        Other:\n\n          -  No other prior malignancy within the past 5 years except basal cell carcinoma of the\n             skin or carcinoma in situ of the cervix\n\n          -  No severe allergy to fish or seafood\n\n          -  No medical condition that would interfere with intake and/or absorption of study\n             medication (e.g., gastrectomy or major intestinal resection)\n\n          -  No significant medical or psychiatric condition that would preclude study\n             participation\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use adequate contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  See Disease Characteristics\n\n          -  No prior history of treatment with thalidomide for more than 14 days duration\n\n          -  At least 4 weeks since prior biological therapy for MM\n\n          -  Concurrent epoetin alfa allowed\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior chemotherapy for MM\n\n        Endocrine therapy:\n\n          -  At least 4 weeks since prior steroid therapy for MM\n\n          -  No prednisone maintenance therapy\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  No concurrent palliative or curative radiotherapy\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  At least 28 days since other prior shark cartilage products\n\n          -  At least 28 days since other prior experimental therapeutic agents\n\n          -  Concurrent monthly bisphosphonate (pamidronates) infusions allowed\n\n          -  No other concurrent anticancer treatment\n\n          -  No other concurrent shark cartilage products\n\n          -  No other concurrent therapies for MM"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "August 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00022282", 
            "org_study_id": "CDR0000068801", 
            "secondary_id": "AETERNA-AE-MM-00-02"
        }, 
        "intervention": {
            "intervention_name": "shark cartilage extract AE-941", 
            "intervention_type": "Drug"
        }, 
        "keyword": "refractory multiple myeloma", 
        "lastchanged_date": "February 27, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/AETERNA-AE-MM-00-02"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Quebec", 
                    "country": "Canada"
                }
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "official_title": "Neovastat (AE-941) in Refractory and Early Relapse Multiple Myeloma Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2007", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00022282"
        }, 
        "source": "AEterna Zentaris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AEterna Zentaris", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2008"
    }, 
    "geocoordinates": {
        "null": "52.94 -73.549"
    }
}